INTRA CELLULAR THERAPIES INC's ticker is ITCI and the CUSIP is 46116X101. A total of 134 filers reported holding INTRA CELLULAR THERAPIES INC in Q1 2019. The put-call ratio across all filers is 0.10 and the average weighting 0.0%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q4 2019 | $5,000 | +400.0% | 150 | 0.0% | 0.00% | – |
Q3 2019 | $1,000 | -50.0% | 150 | 0.0% | 0.00% | – |
Q2 2019 | $2,000 | 0.0% | 150 | 0.0% | 0.00% | – |
Q1 2019 | $2,000 | 0.0% | 150 | 0.0% | 0.00% | – |
Q4 2018 | $2,000 | -33.3% | 150 | 0.0% | 0.00% | – |
Q3 2018 | $3,000 | 0.0% | 150 | 0.0% | 0.00% | – |
Q2 2018 | $3,000 | 0.0% | 150 | 0.0% | 0.00% | – |
Q1 2018 | $3,000 | +50.0% | 150 | 0.0% | 0.00% | – |
Q4 2017 | $2,000 | 0.0% | 150 | 0.0% | 0.00% | – |
Q3 2017 | $2,000 | 0.0% | 150 | 0.0% | 0.00% | – |
Q2 2017 | $2,000 | 0.0% | 150 | 0.0% | 0.00% | – |
Q1 2017 | $2,000 | 0.0% | 150 | 0.0% | 0.00% | – |
Q4 2016 | $2,000 | 0.0% | 150 | 0.0% | 0.00% | – |
Q3 2016 | $2,000 | -66.7% | 150 | 0.0% | 0.00% | – |
Q2 2016 | $6,000 | +50.0% | 150 | 0.0% | 0.00% | – |
Q1 2016 | $4,000 | -50.0% | 150 | 0.0% | 0.00% | – |
Q4 2015 | $8,000 | +33.3% | 150 | 0.0% | 0.00% | – |
Q3 2015 | $6,000 | – | 150 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
TANG CAPITAL MANAGEMENT LLC | 700,000 | $42,833,000 | 8.57% |
SILVERARC CAPITAL MANAGEMENT, LLC | 308,819 | $18,897,000 | 7.82% |
Vahanian & Associates Financial Planning Inc. | 45,533 | $2,786,000 | 6.44% |
DCF Advisers, LLC | 238,500 | $14,594,000 | 6.39% |
INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 50,956 | $20,930,000 | 4.72% |
SUVRETTA CAPITAL MANAGEMENT, LLC | 1,531,923 | $93,738,000 | 2.86% |
Nicholas Investment Partners, LP | 562,373 | $34,412,000 | 2.45% |
Bellevue Group AG | 3,429,619 | $209,859,000 | 2.44% |
WASATCH ADVISORS LP | 7,477,868 | $457,571,000 | 2.25% |
Quantum Private Wealth, LLC | 73,772 | $4,514,000 | 1.95% |